Abstract
The role of aldose reductase in the development of peripheral neuropathy as a late complication of diabetes is discussed and preliminary results of a double blind trial of cyclandelate and placebo in the treatment of diabetic peripheral neuropathy are presented. Examination of the data from the first 16 patients who have completed the study indicates improvement in nerve conductance in the cyclandelate treated group. The possible explanation for the improvement is discussed. Definite conclusions regarding the value of cyclandelate in the treatment of diabetic peripheral neuropathy will have to await the completion of the study.
| Original language | English |
|---|---|
| Pages (from-to) | 62-68 |
| Number of pages | 7 |
| Journal | British Journal of Clinical Practice |
| Volume | 38 |
| Issue number | 6 SUPPL. 34 |
| Publication status | Published - 1984 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Effects of cyclandelate on diabetic peripheral neuropathy. / Canal, N.; Comi, G.; Marchettini, P.; Pozza, G.
In: British Journal of Clinical Practice, Vol. 38, No. 6 SUPPL. 34, 1984, p. 62-68.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effects of cyclandelate on diabetic peripheral neuropathy
AU - Canal, N.
AU - Comi, G.
AU - Marchettini, P.
AU - Pozza, G.
PY - 1984
Y1 - 1984
N2 - The role of aldose reductase in the development of peripheral neuropathy as a late complication of diabetes is discussed and preliminary results of a double blind trial of cyclandelate and placebo in the treatment of diabetic peripheral neuropathy are presented. Examination of the data from the first 16 patients who have completed the study indicates improvement in nerve conductance in the cyclandelate treated group. The possible explanation for the improvement is discussed. Definite conclusions regarding the value of cyclandelate in the treatment of diabetic peripheral neuropathy will have to await the completion of the study.
AB - The role of aldose reductase in the development of peripheral neuropathy as a late complication of diabetes is discussed and preliminary results of a double blind trial of cyclandelate and placebo in the treatment of diabetic peripheral neuropathy are presented. Examination of the data from the first 16 patients who have completed the study indicates improvement in nerve conductance in the cyclandelate treated group. The possible explanation for the improvement is discussed. Definite conclusions regarding the value of cyclandelate in the treatment of diabetic peripheral neuropathy will have to await the completion of the study.
UR - http://www.scopus.com/inward/record.url?scp=0021246865&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021246865&partnerID=8YFLogxK
M3 - Article
VL - 38
SP - 62
EP - 68
JO - British Journal of Clinical Practice
JF - British Journal of Clinical Practice
SN - 0007-0947
IS - 6 SUPPL. 34
ER -